ATE411036T1 - Verwendung von aplidine in der behandlung von pankreaskrebs - Google Patents

Verwendung von aplidine in der behandlung von pankreaskrebs

Info

Publication number: ATE411036T1
Authority: AT; Austria
Prior art keywords: aplidine; treatment; pancreas cancer; cancer; pancreas
Prior art date: 2001-10-19

Application number

AT02770106T

Other languages

English (en)

Inventor

R Mangues

R Henriquez

J Jimeno

Original Assignee

Pharma Mar Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-19

Filing date

2002-10-21

Publication date

2008-10-15

2002-04-15 Priority claimed from GB0208624A external-priority patent/GB0208624D0/en

2002-10-21 Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa

2008-10-15 Application granted granted Critical

2008-10-15 Publication of ATE411036T1 publication Critical patent/ATE411036T1/de

Links

206010061902 Pancreatic neoplasm Diseases 0.000 title abstract 3
208000015486 malignant pancreatic neoplasm Diseases 0.000 title abstract 2
208000008443 pancreatic carcinoma Diseases 0.000 title abstract 2
UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 title abstract 2
229950008499 plitidepsin Drugs 0.000 title abstract 2
108010049948 plitidepsin Proteins 0.000 title abstract 2
230000001394 metastastic effect Effects 0.000 abstract 1
206010061289 metastatic neoplasm Diseases 0.000 abstract 1
201000002528 pancreatic cancer Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT02770106T 2001-10-19 2002-10-21 Verwendung von aplidine in der behandlung von pankreaskrebs ATE411036T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34841201P	2001-10-19	2001-10-19
GB0208624A GB0208624D0 (en)	2002-04-15	2002-04-15	Use of aplidine for the treatment of pancreatic cancer

Publications (1)

Publication Number	Publication Date
ATE411036T1 true ATE411036T1 (de)	2008-10-15

Family

ID=26247033

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02770106T ATE411036T1 (de)	2001-10-19	2002-10-21	Verwendung von aplidine in der behandlung von pankreaskrebs

Country Status (9)

Country	Link
US (2)	US20050004012A1 (de)
EP (1)	EP1435991B1 (de)
AT (1)	ATE411036T1 (de)
AU (1)	AU2002336206B2 (de)
CA (1)	CA2462642A1 (de)
DE (1)	DE60229414D1 (de)
ES (1)	ES2315404T3 (de)
PT (1)	PT1435991E (de)
WO (1)	WO2003033013A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9803448D0 (en)	1998-02-18	1998-04-15	Pharma Mar Sa	Pharmaceutical formulation
CZ302498B6 (cs) *	1999-11-15	2011-06-15	Pharma Mar, S. A.	Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
UA76718C2 (uk)	2000-06-30	2006-09-15	Фарма Мар, С.А.	Протипухлинні похідні аплідину
IL155273A0 (en)	2000-10-12	2003-11-23	Pharma Mar Sa	Pharmaceutical compositions comprising an aplidine compound
EP1620117A4 (de)	2003-03-12	2009-07-29	Pharma Mar Sa	Verbesserte antitumorale behandlungen
AU2004218883B2 (en)	2003-03-12	2009-10-01	Dana-Farber Cancer Institute, Inc.	Aplidine for multiple myeloma treatment
WO2007101235A2 (en) *	2006-02-28	2007-09-07	Pharma Mar, S.A.	Improved antitumoral treatments
WO2008080956A1 (en) *	2006-12-29	2008-07-10	Pharma Mar, S.A.	Prognostic molecular markers for the cancer therapy with aplidine
AU2008313627A1 (en) *	2007-10-19	2009-04-23	Pharma Mar, S.A.	Improved antitumoral treatments
CA2717409A1 (en) *	2008-03-07	2009-09-11	Pharma Mar, S.A.	Improved anticancer treatments
KR102491180B1 (ko)	2017-04-27	2023-01-20	파르마 마르 에스.에이.	항종양 화합물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4342744A (en) *	1979-07-19	1982-08-03	Lever Brothers Company	Hair treatment products
US4493796A (en) *	1980-09-12	1985-01-15	Board Of Trustees, Univ. Of Ill.	Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) *	1980-09-12	1990-08-21	University Of Illinois	Didemnins and nordidemnins
IT1153974B (it) *	1982-09-23	1987-01-21	Erba Farmitalia	Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
GB8922026D0 (en) *	1989-09-29	1989-11-15	Pharma Mar Sa	Novel anti-viral and cytotoxic agent
FR2698543B1 (fr) *	1992-12-02	1994-12-30	Rhone Poulenc Rorer Sa	Nouvelles compositions à base de taxoides.
US5462726A (en) *	1993-12-17	1995-10-31	Bristol-Myers Squibb Company	Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
JPH09507233A (ja) *	1993-12-29	1997-07-22	マトリクスファーマスーティカル，インコーポレイティド	細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
US5861439A (en) *	1994-11-14	1999-01-19	Alza Corporation	Method for enhanced electrotransport agent delivery
US6365597B1 (en) *	1996-02-14	2002-04-02	Aventis Pharmaceuticals Inc.	4-aza steroids
ES2151277T3 (es) *	1996-05-22	2000-12-16	Protarga Inc	Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6156724A (en) *	1996-06-07	2000-12-05	Rinehart; Kenneth L.	Uses of didemnins as immunomodulating agents
US6034058A (en) *	1997-04-15	2000-03-07	Rinehart; Kenneth L.	Semi-synthetic alanyl dilemnin analogs
US6030943A (en) *	1997-05-07	2000-02-29	Crumb; William J.	Dehydrodidemnin B as an L-type calcium channel enhancer
CA2338638C (en) *	1998-07-30	2009-03-17	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US20010021380A1 (en) *	1999-04-19	2001-09-13	Pluenneke John D.	Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) *	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
CZ302498B6 (cs) *	1999-11-15	2011-06-15	Pharma Mar, S. A.	Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
US6509315B1 (en) *	2000-04-07	2003-01-21	The Trustees Of The University Of Pennsylvania	Didemnin analogs and fragments and methods of making and using them
AU1305302A (en) *	2000-10-05	2002-04-15	Immunex Corp	Nectin polypeptides, polynucleotides, methods of making and use thereof
WO2002032374A2 (en) *	2000-10-18	2002-04-25	Immunex Corporation	Methods for treating il-18 mediated disorders

2002
- 2002-10-21 DE DE60229414T patent/DE60229414D1/de not_active Expired - Lifetime
- 2002-10-21 EP EP02770106A patent/EP1435991B1/de not_active Expired - Lifetime
- 2002-10-21 CA CA002462642A patent/CA2462642A1/en not_active Abandoned
- 2002-10-21 US US10/492,659 patent/US20050004012A1/en not_active Abandoned
- 2002-10-21 AU AU2002336206A patent/AU2002336206B2/en not_active Ceased
- 2002-10-21 WO PCT/GB2002/004816 patent/WO2003033013A1/en not_active Ceased
- 2002-10-21 PT PT02770106T patent/PT1435991E/pt unknown
- 2002-10-21 ES ES02770106T patent/ES2315404T3/es not_active Expired - Lifetime
- 2002-10-21 AT AT02770106T patent/ATE411036T1/de not_active IP Right Cessation
2009
- 2009-10-23 US US12/604,900 patent/US20100041594A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2003033013A1 (en)	2003-04-24
EP1435991A1 (de)	2004-07-14
US20100041594A1 (en)	2010-02-18
EP1435991B1 (de)	2008-10-15
DE60229414D1 (de)	2008-11-27
CA2462642A1 (en)	2003-04-24
ES2315404T3 (es)	2009-04-01
PT1435991E (pt)	2009-01-16
US20050004012A1 (en)	2005-01-06
AU2002336206B2 (en)	2007-11-29

Legal Events

Date	Code	Title	Description
2009-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
BR9707233A (pt)	1999-07-20	Fenantridinas
DE60111570D1 (de)	2005-07-21	Isoindolin-1-on als glukokinaseaktivatoren
EA200100731A1 (ru)	2002-02-28	Фенилфенантридины с ингибирующей фдэ-4 активностью
DE60031248D1 (de)	2006-11-23	Elektroaktive pore
DE60033658D1 (de)	2007-04-12	Behandlung von prostata-krebs mit anti-erbb2 antikörpern
ATE348616T1 (de)	2007-01-15	2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de)	2007-02-15	3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
DE60040981D1 (de)	2009-01-15	BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
TR199902751T2 (xx)	2000-02-21	Proteaz inhibit�rleri.
TR200103216T2 (tr)	2002-04-22	Pirimidinon bileşimleri
DK0889886T3 (da)	2003-01-20	Hidtil ukendte, i 6-stilling substituerede phenanthridiner
DK0998460T3 (da)	2004-07-05	Hidtil ukendte tetrazolderivater
DE60108857D1 (de)	2005-03-17	Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE411036T1 (de)	2008-10-15	Verwendung von aplidine in der behandlung von pankreaskrebs
ATE356810T1 (de)	2007-04-15	Polysubstituted 6-phenylphenanthridines mit pde- iv hemmender wirkung
ATE363531T1 (de)	2007-06-15	Claudin polypeptide
DE60019894D1 (de)	2005-06-09	Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
DE60025327D1 (de)	2006-03-30	6-arylphenanthridine mit pde-iv hemmender wirkung
DK1214061T3 (da)	2004-11-01	Anvendelse af docetaxel til behandling af hepatocellulært carcinom
PT1147087E (pt)	2005-09-30	Feantridina-n-oxidos com actividade de inibicao de pde-iv
SE0301654D0 (sv)	2003-06-05	Novel compounds
DE60101906D1 (de)	2004-03-04	Phenyl-substituierte indolizinderivate und deren verwendung als histamin h3 liganden
TR200402322T4 (tr)	2004-12-21	Triptaz inhibitörler
ATE268322T1 (de)	2004-06-15	Inhibitoren der tryptase
TR200003084T2 (tr)	2001-02-21	Paroxetine askorbat